Nurix Therapeutics, Inc. (NRIX)

Market Cap	1.28B
Revenue (ttm)	54.55M
Net Income (ttm)	-193.57M
Shares Out	75.89M
EPS (ttm)	-2.88
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	507,878
Open	17.25
Previous Close	17.04
Day's Range	16.75 - 17.46
52-Week Range	10.17 - 29.56
Beta	2.14
Analysts	Strong Buy
Price Target	31.75 (+88.2%)
Earnings Date	Apr 9, 2025

About NRIX

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase 1A clinical trials f...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 24, 2020
• Employees: 286
• Stock Exchange: NASDAQ
• Ticker Symbol: NRIX
• Website: https://www.nurixtx.com

Financial Performance

In 2024, Nurix Therapeutics's revenue was $54.55 million, a decrease of -29.15% compared to the previous year's $76.99 million. Losses were -$193.57 million, 34.5% more than in 2023.

Analyst Forecast

According to 16 analysts, the average rating for NRIX stock is "Strong Buy." The 12-month stock price forecast is $31.75, which is an increase of 88.20% from the latest price.

Price Target

$31.75

(88.20% upside)

Analyst Consensus: Strong Buy